Catalent Inc (NYSE:CTLT)
| 95.46 Delayed Data As of Dec 04 |  +1.99 / +2.13%Today’s Change | 31.04 Today|||52-Week Range 120.48 | +69.56% Year-to-Date |
Latest CTLT News | Press Releases
| JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising Dec 04 / Zacks.com - Paid Partner Content | Looking for a Growth Stock? Why It is Time to Focus on Catalent (CTLT) Nov 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 93.47 |
| Today’s open | 93.36 |
| Day’s range | 93.36 - 95.46 |
| Volume | 1,707,357 |
| Average volume (3 months) | 1,417,376 |
| Market cap | $16.0B |
Data as of 4:00pm ET, 12/04/2020
Growth & Valuation
| Earnings growth (last year) | +26.20% |
| Earnings growth (this year) | +20.56% |
| Earnings growth (next 5 years) | +18.34% |
| Revenue growth (last year) | +22.89% |
| P/E ratio | 59.6 |
| Price/Sales | 3.61 |
| Price/Book | 5.47 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| HZNPHorizon Therapeutics... | +0.43 | +0.60% |
| ALNYAlnylam Pharmaceutic... | -1.66 | -1.27% |
| INCYIncyte Corp | +0.26 | +0.31% |
| SRPTSarepta Therapeutics... | +4.72 | +3.08% |
Data as of 5:43pm ET, 12/04/2020
Financials
| Next reporting date | February 8, 2021 |
| EPS forecast (this quarter) | $0.56 |
| Annual revenue (last year) | $3.1B |
| Annual profit (last year) | $173.0M |
| Net profit margin | 5.59% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Somerset, New Jersey |
Forecasts
